Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy.
Daniela J Conrado, Jane Larkindale, Alexander Berg, Micki Hill, Jackson Burton, Keith R Abrams, Richard T Abresch, Abby Bronson, Douglass Chapman, Michael Crowther, Tina Duong, Heather Gordish-Dressman, Lutz Harnisch, Erik Henricson, Sarah Kim, Craig M McDonald, Stephan Schmidt, Camille Vong, Xiaoxing Wang, Brenda L Wong Show all
J Pharmacokinet Pharmacodyn | Published : 2019
Drug development for rare diseases is challenged by small populations and limited data. This makes development of clinical trial protocols difficult and contributes to the uncertainty around whether or not a potential therapy is efficacious. The use of data standards to aggregate data from multiple sources, and the use of such integrated databases to develop statistical models can inform protocol development and reduce the risks in developing new therapies. Achieving regulatory endorsement of such models through defined pathways at the US Food and Drug Administration and European Medicines Authority allows such tools to be used by the drug development community for defined contexts of use wi..View full abstract
Awarded by FDA HHS